BiotechTube

STAT3 Inhibitor WP1066

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioblastoma, IDH-Wildtype

Conditions

Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma

Trial Timeline

May 22, 2024 → Dec 27, 2028

NCT ID
NCT05879250

About STAT3 Inhibitor WP1066

STAT3 Inhibitor WP1066 is a phase 2 stage product being developed by Moleculin Biotech for Glioblastoma, IDH-Wildtype. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05879250. Target conditions include Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05879250Phase 2Recruiting

Competing Products

20 competing products in Glioblastoma, IDH-Wildtype

See all competitors
ProductCompanyStageHype Score
TemferonGenenta SciencePhase 1/2
33
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
PLX3397Daiichi SankyoPhase 2
52
ASP8374 + cemiplimabAstellas PharmaPhase 1
33
Nimotuzumab + TemozolomideSun PharmaceuticalPhase 2
52
Gliadel + Avastin + TemodarEisaiPhase 2
52
BCNU Wafer + Irinotecan + BevacizumabEisaiPhase 1/2
41
KHK2455Kyowa KirinPre-clinical
23
olaratumab + ramucirumabEli LillyPhase 2
52
enzastaurin + temozolomideEli LillyPhase 1/2
41
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)Eli LillyPhase 2
52
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115Eli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)Eli LillyPhase 2
52
Abemaciclib + LY3214996Eli LillyPhase 1
33
enzastaurin + lomustineEli LillyPhase 3
77
Galunisertib + Lomustine + PlaceboEli LillyPhase 2
52
DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
77
DSP-7888Sumitomo PharmaPhase 1/2
41
BBI608 + TemozolomideSumitomo PharmaPhase 1/2
41

Other Products from Moleculin Biotech

Placebo in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin for Injection in combination with Cytarabine Injection.Phase 2/3
57
Liposomal Annamycin + CytarabinePhase 1/2
33
Liposomal AnnamycinPhase 1/2
33
Liposomal Annamycin (L-Annamycin)Phase 1/2
33
Liposomal AnnamycinPhase 1/2
33